False
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View Profile
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
All the latest Medicine Maker articles.
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
September 29, 2026
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
5 min read
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
September 25, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the regulatory, manufacturing, investment, and commercialization trends signaling a new phase for advanced therapies
1 min read
September 24, 2026
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
2 min read
September 23, 2026
Scientific breakthroughs are only true innovations if healthcare systems can deliver them safely, manage their toxicities, and make them accessible at scale
6 min read
September 23, 2026
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
2 min read
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
False
